EP0906440A1 - Verfahren zur transduktion von zellen in blutgefässen unter verwendung von rekombinanten aav vektoren - Google Patents
Verfahren zur transduktion von zellen in blutgefässen unter verwendung von rekombinanten aav vektorenInfo
- Publication number
- EP0906440A1 EP0906440A1 EP97907934A EP97907934A EP0906440A1 EP 0906440 A1 EP0906440 A1 EP 0906440A1 EP 97907934 A EP97907934 A EP 97907934A EP 97907934 A EP97907934 A EP 97907934A EP 0906440 A1 EP0906440 A1 EP 0906440A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell
- cells
- blood vessel
- transducing
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 99
- 239000013598 vector Substances 0.000 title claims abstract description 97
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 78
- 230000002463 transducing effect Effects 0.000 title claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 97
- 238000001727 in vivo Methods 0.000 claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims description 218
- 210000001367 artery Anatomy 0.000 claims description 47
- 210000004088 microvessel Anatomy 0.000 claims description 46
- 239000013608 rAAV vector Substances 0.000 claims description 33
- 210000002808 connective tissue Anatomy 0.000 claims description 17
- 239000003550 marker Substances 0.000 claims description 13
- 230000002062 proliferating effect Effects 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 241000288906 Primates Species 0.000 claims description 9
- 210000001736 capillary Anatomy 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 9
- 210000004925 microvascular endothelial cell Anatomy 0.000 claims description 8
- 210000002565 arteriole Anatomy 0.000 claims description 7
- 210000000264 venule Anatomy 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 abstract description 18
- 238000012546 transfer Methods 0.000 abstract description 11
- 241000702421 Dependoparvovirus Species 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000010361 transduction Methods 0.000 description 50
- 230000026683 transduction Effects 0.000 description 50
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 31
- 108091033319 polynucleotide Proteins 0.000 description 29
- 102000040430 polynucleotide Human genes 0.000 description 29
- 239000002157 polynucleotide Substances 0.000 description 29
- 241000282414 Homo sapiens Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 24
- 210000001715 carotid artery Anatomy 0.000 description 23
- 210000002889 endothelial cell Anatomy 0.000 description 22
- 239000002245 particle Substances 0.000 description 20
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 19
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- 239000013607 AAV vector Substances 0.000 description 16
- 241000700605 Viruses Species 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000002203 pretreatment Methods 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 108700038605 human Smooth muscle Proteins 0.000 description 8
- 210000005166 vasculature Anatomy 0.000 description 8
- 230000003143 atherosclerotic effect Effects 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 210000003038 endothelium Anatomy 0.000 description 7
- 238000001476 gene delivery Methods 0.000 description 7
- 102000043827 human Smooth muscle Human genes 0.000 description 7
- 238000012760 immunocytochemical staining Methods 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 210000001604 vasa vasorum Anatomy 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 241000282553 Macaca Species 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229960001134 von willebrand factor Drugs 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000006862 enzymatic digestion Effects 0.000 description 5
- 210000001105 femoral artery Anatomy 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108010047303 von Willebrand Factor Proteins 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000036770 blood supply Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108700038606 rat Smooth muscle Proteins 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 102100031102 C-C motif chemokine 4 Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- -1 GRO MGSA Proteins 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 208000009443 Vascular Malformations Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 238000013156 embolectomy Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000005063 microvascular endothelium Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 230000001453 nonthrombogenic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000002747 omentum Anatomy 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 1
- 101710155835 C-C motif chemokine 1 Proteins 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 101710155855 C-C motif chemokine 4 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101150029409 CFTR gene Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000777471 Homo sapiens C-C motif chemokine 4 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010069384 Ischaemic nephropathy Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100268515 Mus musculus Serpina1b gene Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- LHLHVDBXXZVYJT-RRKCRQDMSA-N [(2r,3s,5r)-5-(5-bromo-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(Br)=C1 LHLHVDBXXZVYJT-RRKCRQDMSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 108010023079 activin B Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000002945 adventitial reticular cell Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 101150067977 ap gene Proteins 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- RYNBQQWODYCGRR-UHFFFAOYSA-N ethyl 5-(4-chlorophenyl)-2-methyl-1-phenylpyrrole-3-carboxylate Chemical compound C=1C=CC=CC=1N1C(C)=C(C(=O)OCC)C=C1C1=CC=C(Cl)C=C1 RYNBQQWODYCGRR-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 108010067471 inhibin A Proteins 0.000 description 1
- 108010067479 inhibin B Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002697 interventional radiology Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004619 light microscopy Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000010469 pro-virus integration Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- This invention relates to gene delivery, and more specifically to methods for transducing cells in blood vessels using recombinant aden ⁇ -associated virus (AAV) vectors.
- AAV aden ⁇ -associated virus
- Blood vessels a major component ofthe cardiovascular system, form a network that permits blood to flow from the heart to cells throughout the body and back to the heart.
- blood vessels are composed of three layers, the intima, media and adventitia.
- the intima in most undiseased arterial vessels generally comprises a luminal monolayer of endothelial cells.
- the intima may contain smooth muscle cells; and, in diseases such as atherosclerosis, the intima may thicken with smooth muscle cells and inflammatory cells beneath the endothelial monolayer.
- the intima is separated from the media by the internal elastic lamina.
- the media generally comprises smooth muscle cells and their surrounding matrix material.
- the media is composed of defined layers of smooth muscle cells separated by elastic fibers.
- the adventitia forms the outermost layer of the artery wall and is separated from the media by the external elastic lamina.
- the adventitia is generally composed of a loose matrix containing macrophages, fibroblasts, and other cell types, as well as the vasa vasorum (a rich network of adventitial micro vessels).
- Microvessels may differ from the general structural model outlined above in that the three layers may not be well defined.
- capillaries may comprise a monolayer of endothelial cells surrounded by a single layer of smooth muscle cells without any well-defined elastic layers.
- Angiogenesis is the formation of new blood vessels. Angiogenesis occurs during fetal development ofthe vascular system, as well in a wide range of normal and postnatal pathological processes such as wound repair; neoplasia, and inflammation. [See, e.g., Diaz-Flores, 1994] Thus, a number of disease processes have abundant microvessels as key anatomical or pathological features.
- microvessels may contribute directly or indirectly to the development of specific illnesses or may represent a benign morphological feature.
- microvessels and angiogenesis are believed to play central roles in the pathogenesis of disease. These include, for example, the growth and metastasis of many cancers, diabetic retinopathy, retinitis, heart failure, arthritis, psoriasis, ischemia, wound healing, hemangiomas and other vascular malformations. [See, e.g., Diaz-Flores, 1994]
- the cells comprising all tissues and organs require an extensive network of microvessels to support their normal function and viability. Since these microvessels may be functionally unique and distinct from larger blood vessels, microvessels provide unique targets for delivery of therapeutic polynucleotides to tissues.
- the tissue or organ may be enhanced in a positive way.
- retroviral vectors are advantageous because of their general potential for stable long-term gene expression, target cell replication is required for stable provirus integration.
- most cells in the artery are generally quiescent.
- Quiescent cells can sometimes be isolated and induced to divide in order to achieve significant and efficient gene transfer; but, this method often requires that the cells be induced and genetically modified ex vivo and thereafter transplanted back into the donor host.
- Liposomal vector delivery systems have also been limited by inefficient uptake and transient episomal vector expression.
- Adenoviral vectors that have been efficient at infecting endothelial cells have been limited by transient episomal vector expression and by antigenicity limiting the efficacy of repeated applications.
- the present invention provides methods for transducing cells in blood vessels using recombinant AAV vectors.
- Preferred embodiments ofthe present invention include the following: 1. A method of transducing a cell in a blood vessel of an individual, comprising introducing a recombinant adeno-associated viral (rAAV) vector to a blood vessel of said individual in vivo.
- rAAV adeno-associated viral
- a method of transducing a cell in a blood vessel according to embodiment 1 wherein said rAAV vector comprises a detectable marker gene.
- said rAAV vector comprises a selectable marker gene.
- a method of transducing a cell in a blood vessel according to embodiment 1 wherein said blood vessel is a microvessel selected from the group consisting of arteriole, capillary, venule, and adventitial microvessel.
- a method of transducing a cell in a blood vessel according to embodiment 1 wherein said blood vessel is a microvessel and said cell is undergoing proliferation.
- a method of transducing a cell in a blood vessel according to embodiment 1 wherein said cell is a proliferating cell.
- a transduced microvascular cell produced by introducing a recombinant adeno-associated viral (rAAV) vector to said microvascular cell.
- rAAV adeno-associated viral
- a method for treating an individual for a disease condition comprising transducing a cell in a blood vessel of said individual according to the method of embodiment 4.
- Polynucleotide refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides, or analogs thereof. This term refers only to the primary structure ofthe molecule. Thus, double- and single-stranded
- DNA as well as double- and single-stranded RNA are included. It also includes modified polynucleotides such as methylated or capped polynucleotides.
- Recombinant as applied to a polynucleotide, means that the polynucleotide is the product of various combinations of cloning, restriction and/or ligation steps, and other procedures that result in a construct that is distinct from a polynucleotide found in nature.
- a “vector” refers to a recombinant plasmid or virus that comprises a polynucleotide to be delivered into a host cell, either in vitro or in vivo.
- the polynucleotide to be delivered may comprise a coding sequence of interest in gene therapy.
- a “recombinant AAV vector” refers to a vector comprising one or more polynucleotides of interest that are flanked by AAV inverted terminal repeat sequences (ITRs).
- ITRs AAV inverted terminal repeat sequences
- One possible method of replicating and packaging a rAAV vector into infectious viral particles may be to introduce the rAAV vector into a host cell expressing the AAV "rep” and “cap” genes and infected with a suitable helper virus.
- a “gene” refers to a polynucleotide or portion of a polynucleotide comprising a sequence that encodes a protein. For most situations, it is desirable for the gene to also comprise a promoter operably linked to the coding sequence in order to effectively promote transcription. Enhancers, repressors and other regulatory sequences may also be included in order to modulate activity ofthe gene, as is well known in the art. (See, e.g., the references cited below).
- polypeptide As used interchangeably to refer to polymers of amino acids of any length. These terms also include proteins that are post-translationally modified through reactions that include glycosylation, acetylation and phosphorylation.
- AAV "rep” and “cap” genes encoding replication and encapsidatio ⁇ proteins, respectively, have been found in all AAV serotypes examined, as described in various references cited herein. Typically, the rep and cap genes are found adjacent to each other in the AAV genome, and they are generally conserved among AAV serotypes.
- helper virus for AAV refers to a second virus that allows wild-type AAV, which is a defective parvovirus, to be replicated and packaged by a host cell.
- helper viruses have been identified in the art, including adenoviruses, herpesviruses, and poxviruses such as vaccinia.
- Packaging refers to a series of subcellular events that results in the assembly and encapsidation of a rAAV vector. Thus, when a suitable vector plasmid is introduced into a packaging cell line under appropriate conditions, it can be replicated and assembled into a viral particle.
- Heterologous means derived from a genotypically distinct entity from that ofthe rest of the entity to which it is compared.
- a polynucleotide derived from one cell type and introduced by genetic engineering techniques into a different cell type is a heterologous polynucleotide which, when expressed, can encode a heterologous polypeptide.
- a promoter that is removed from its native coding sequence and operably linked to a different coding sequence is a heterologous promoter.
- Promoter refers to a genomic region that controls the transcription of a gene or coding sequence to which it is operably linked.
- “Operably linked” refers to a juxtaposition, wherein the components so described are in a relationship permitting them to function in their intended manner.
- a promoter is operably linked to a coding sequence if the promoter controls transcription of the coding sequence.
- An operably linked promoter is usually in cis configuration with the coding sequence, but is not necessarily contiguous with it.
- a “detectable marker gene” is a gene that allows cells carrying the gene to be specifically detected (e.g., distinguished from cells which do not carry the marker gene).
- a large variety of such marker genes are known in the art. Preferred examples thereof include detectable marker genes which encode proteins appearing on cellular surfaces, thereby facilitating simplified and rapid detection and/or cellular sorting.
- the inventors utilized an alkaline phosphatase ("AP") gene as a detectable marker, which allowed cells transduced with a vector carrying the AP gene to be detected based on expression of AP on the surface of transduced cells.
- AP alkaline phosphatase
- a “selectable marker gene” is a gene that allows cells carrying the gene to be specifically selected for or against, in the presence of a corresponding selective agent.
- an antibiotic resistance gene can be used as a positive selectable marker gene that allows a host cell to be positively selected for in the presence ofthe corresponding antibiotic.
- positive and negative selectable markers are knowii in the art, some of which are described below.
- a “therapeutic polynucleotide” or “therapeutic gene” refers to a nucleotide sequence that is capable, when transferred to an individual, of eliciting a prophylactic, curative or other beneficial effect in the individual.
- Cytokine refers to intercellular signaling molecules, the best known of which are involved in the regulation of mammalian somatic cells.
- interleukins such as IL-l ⁇ , IL-l ⁇ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9 (P40), IL-10, IL-11, IL-12 and IL-13
- CSF-type cytokines such as GM-CSF, G-CSF, M-CSF, LIF, EPO, TNF- ⁇ and TNF- ⁇
- interferons such as IFN- ⁇ , IFN- ⁇ , IFN- ⁇
- cytokines of the TGF- ⁇ family such as TGF- ⁇ 1 , TGF- ⁇ 2, TGF- ⁇ 3, inhibin A, inhibin B, activin A, activin B): chemotin
- growth factors such as EGF, TGF- ⁇ , aFGF, bFGF, KGF, PDGF-A, PDGF-B, PD-ECGF
- cytokines A number of other cytokines are also known to those of skill in the art. The sources, characteristics, targets and effector activities of these cytokines have been described and, for many of the cytokines, the DNA sequences encoding the molecules are also known; see, e.g., Callard & Gearing, The Cytokine Facts Book (Academic Press, 1994) and the particular publications reviewed and/or cited therein, which are hereby incorporated by reference in their entirety. As referenced in catalogs such as The Cytokine Facts Book, many ofthe DNA and/or protein sequences encoding such cytokines are also generally available from sequence databases such as GENBANK (DNA); and SWISSPROT (protein).
- cytokines typically, cloned DNA encoding such cytokines will already be available as plasmids, although it is also possible to synthesize polynucleotides encoding the cytokines based upon the published sequence information. Polynucleotides encoding the cytokines can also be obtained using polymerase chain reaction (PCR) methodology, as described in the art.
- PCR polymerase chain reaction
- the detection, purification, and characterization of cytokines, including assays for identifying new cytokines effective upon a given cell type, have also been described in a number of publications as well as the references referred to herein. [See, e.g., Lymphokines and Interferons. (Clemens, J.J. et al. eds., IRL Press 1987); and DeMaeyer, 1988].
- Transduction or “transducing” as used herein, are terms referring to the introduction of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, which methods include well-known techniques such as transfection, lipofection, viral infection, transformation, and electroporation, as well as non-viral gene delivery techniques.
- the introduced polynucleotide may be stably or transiently maintained in the host cell. Stable maintenance typically requires that the introduced polynucleotide either contains an origin of replication compatible with the host cell or integrates into a replicon of the host cell such as an extrachromosomal replicon (e.g., a plasmid) or a nuclear or mitochondrial chromosome.
- a “replicon” refers to a polynucleotide comprising an origin of replication, generally referred to as an on sequence, which allows for replication ofthe polynucleotide in an appropriate host cell.
- examples include replicons of a target cell into which a desired nucleic acid might integrate, e.g., nuclear and mitochondrial chromosomes, and extrachromosomal replicons such as plasmids.
- an “individual” as used herein refers to a mammal, preferably a human.
- “Treatment” or “therapy” as used herein refers to administering cells, other agents, or combinations thereof, to an individual, that are capable of eliciting a prophylactic, curative or other beneficial effect in the individual.
- Gene delivery refers to the introduction of an exogenous polynucleotide into a cell for gene transfer, and may encompass targeting, binding, uptake, transport, localization, replicon integration and expression.
- Gene transfer refers to the introduction of an exogenous polynucleotide into a cell which may encompass targeting, binding, uptake, transport, localization and replicon integration, but is distinct from and does not imply subsequent expression ofthe gene.
- Gene expression or “expression” refers to the process of gene transcription, translation, and posttranslational modification.
- Vasculature or "vascular” are terms referring to the system of vessels carrying blood (as well as lymph fluids) throughout the mammalian body.
- Blood vessel refers to any ofthe vessels ofthe mammalian vascular system, including arteries, arterioles, capillaries, venules, veins, sinuses, and vasa vasorum.
- the wall of an artery consists typically of an outer layer (adventitia) separated by an external elastic lamina from a middle layer (media) which is separated by an internal elastic lamina from an inner layer (intima).
- the adventitia is a layer of loose connective tissue which generally includes a network of microvessels (vasa vasorum), fibroblasts, and immune cells such as lymphocytes and macrophages.
- the media comprises circular layers of smooth muscle cells and elastic fibers.
- the intima is made up of a monolayer of endothelial cells overlying, in some instances, smooth muscle cells.
- Microvessel “microvascular” or “microvasculature,” as used herein, are terms referring to the arterioles, capillaries, venules, and adventitial microvessels. Microvessels generally comprise endothelial cells surrounded by one or a few layers of smooth muscle cells. Arteriole refers to a minute arterial branch, especially one just proximal to a.capillary. Capillary refers to any one ofthe minute vessels that connect the arterioles and venules, forming a network in virtually all organs and tissues. Venules refer to any ofthe small vessels that collect blood from the capillary plexuses and join to form veins.
- Advanced microvessel refers to microvessels that supply blood to the adventitia of larger blood vessels such as arteries.
- the network of these adventitial microvessels is commonly referred to as the vasa vasorum.
- adventitial microvessels are believed to be supplied with blood from the lumen ofthe parent vessel (e.g., the artery) via small microvessels traversing the vessel intima and media.
- Microvascular cell refers to cells that make up the structure of microvessels.
- Endothelium refers to the layer of cells (i.e., “endothelial cells”) that generally lines the cavities ofthe heart and blood vessels, as well as vessels ofthe lymphatic system.
- vessels such as arteries can contain both endothelial cells and smooth muscle cells which are distinguishable in terms of origin, functionality, and attributes such as cell surface markers.
- endothelial cells derive from embryonic ectoderm, form the layer of cells that make up the endothelium, provide a non-thrombogenic surface, and can be readily distinguished using a number of well-known cell surface markers, including, by way of illustration, vWF, as exemplified below.
- smooth muscle cells derive from embryonic mesoderm, provide structure and contractile function for blood vessel walls, do not provide a non-thrombogenic surface, and can be readily distinguished using a number of well-known surface markers, including, by way of illustration, alpha-actin, as exemplified below.
- "Proliferating” or “proliferation” are terms referring to growth by cell multiplication.
- Angiogenesis is the formation of new blood vessels which occurs during fetal development of the vascular system, as well in a wide range of normal and postnatal pathological processes such as wound repair, neoplasia, and inflammation.
- Additional references describing delivery and logistics of surgery which may be used in the methods ofthe present invention include the following: The Textbook of Interventional Cardiology. 2nd Ed. (E. Topol ed., W.B. Saunders Co. 1994); Rutherford, R.B., Vascular Surgery. 3rd Ed. (W.B. Saunders Co. 1989); Interventional Radiology. 2nd Edition (W. Castaneda-Zuniga & S. Tadavarthy eds., Williams & Wilkins 1992); Textbook of Respiratory Medicine. 2nd Ed. (J. Murray & J. Nadel eds., W.B. Saunders Co. 1994); and Textbook of Sureerv. 14th Ed. (D. Sabiston, Jr., W.B. Saunders Co. 1991).
- Additional references describing cell types found in the blood vessels, and the structure ofthe vasculature which may be used in the methods ofthe present invention include the following: W. Bloom & D. Fawcett, A Textbook of Histology. 10th Ed.. (W.B. Saunders Co. 1975). Additional references describing AAV vectors which may be used in the methods ofthe present invention include the following: Carter, B., Handbook of Parvoviruses. vol. I, pp. 169-228 (1990); Berns, Virology, pp. 1743-1764 (Raven Press 1990); Muzyczka. N.. Current Topics in Microbiology and Immunology. 158: 92-129 (1992); and Kotin, R., Human Gene Therapy. 5: 793-801 (1994).
- Carter, B. Handbook of Parvoviruses. vol. I, pp. 169-228 (1990). Carter, B., Current Opinions in Biotechnology. 3: 533-539 (1992).
- the invention described involves methods for transducing cells in blood vessels using recombinant AAV vectors.
- the transduction of cells in blood vessels in vivo presents problems not encountered in the transduction of other cells in vivo or in vitro.
- AAV vectors are among a small number of recombinant virus vector systems which have been shown to have utility as in vivo gene transfer agents and thus are potentially of great importance for human gene therapy.
- AAV vectors are capable of high-frequency gene transfer and expression in a variety of cell lines ex vivo. [Carter, 1992; Egan, 1992; Flotte, 1992; Flotte (1 ), 1993; Flotte (2), 1993: Kaplitt, 1994; Kotin, 1994; Muzyczka, 1992; and Walsh, 1992]
- AAV is a DNA parvovirus often found in association with adenovirus infections of humans.
- AAV has not been shown to cause disease in man and is not a transforming or oncogenic virus.
- most ofthe other proposed viral systems such as retroviruses, adeno viruses, herpesviruses, or poxviruses are disease-causing viruses. Indeed, greater than 85% of adults are believed to be seropositive for one of four AAV serotypes.
- AAV is also replication-defective, and can replicate only within the nucleus of cells simultaneously infected with a helper virus such as adenovirus, herpes virus, or in some cases poxviruses such as vaccinia.
- AAV is believed to be capable of infecting and replicating (albeit at different efficiencies) in virtually any cell line of human, simian or rodent origin if an appropriate helper is present.
- AAV has a clear advantage over retroviruses, especially in tissues such as the human airway epithelium where most cells are terminally differentiated and non-dividing, because AAV does not require active cell division for gene transfer.
- retroviruses are capable of transducing quiescent cells in situ and have recently been shown to be effective at transducing monkey pulmonary epithelium in vivo with the CFTR gene for cystic fibrosis. [See, e.g., Flotte, 1994] These studies have recently been carried into human trials approved by the NIH Recombinant DNA Advisory Committee.
- AAV can be modified to create a vector for the delivery of heterologous genes.
- such AAV vectors will have no wild-type coding sequences and will be incapable of replication, even in the presence of helper virus.
- the process of modification involves deleting all wild-type AAV coding sequences (rep and cap) so that only the inverted terminal repeat sequences (which are required in cis for vector replication) remain.
- a gene of interest can be inserted between the viral inverted terminal repeat sequences and then packaged.
- AAV vectors can be constructed in AAV recombinant plasmids by substituting portions of the AAV coding sequence with heterologous DNA to generate a vector plasmid.
- the terminal (ITR) portions ofthe AAV sequence play an important role in cis for several functions including excision from the plasmid after transfection, replication of the vector genome and integration and rescue from a host cell genome.
- the vector can then be packaged into an AAV particle to generate an AAV transducing virus by transfection ofthe vector plasmid into cells that are: (1) infected by an appropriate helper virus such as adenovirus or herpesvirus, and (2) capable of providing AAV replication and encapsidation functions in trans (since these functions were deleted in construction ofthe vector plasmid).
- helper virus such as adenovirus or herpesvirus
- AAV replication and encapsidation functions in trans since these functions were deleted in construction ofthe vector plasmid.
- recombinant AAV vector preparations can comprise AAV ITR regions and a transcription promoter operably linked to any gene of interest that is to be transduced to the recipient cell, including for example, detectable genes, selectable genes, and/or therapeutic genes.
- detectable genes include detectable genes, selectable genes, and/or therapeutic genes.
- the inventors used human placental alkaline phosphatase (AP) as a detectable gene.
- AP placental alkaline phosphatase
- other recombinant AAV vectors containing one or more detectable, selectable, and/or therapeutic genes can be readily employed.
- the methods ofthe present invention can employ rAAV vectors comprising (in place of or in addition to a detectable and/or selectable gene) a therapeutic gene that is used to alter the activity ofthe transduced recipient cell so that the recipient cell and/or its progeny have a beneficial effect on an individual receiving such cells.
- a typical example would be the transduction of cells in a blood vessel with a therapeutic gene that enhances the level of a beneficial protein or other agent in the cell and or its progeny, or that reduces the level of a deleterious protein or other agent in the cell and/or its progeny, or that provides resistance to a cytotoxic or other harmful agent.
- the present invention can be used to transduce cells in a blood vessel with a gene or genes that encode secreted proteins or that encode proteins involved in the secretion of other agents from the cell and/or its progeny, which secreted proteins or other agents have a beneficial effect on the recipient individual.
- the present invention can be used to transduce cells in a blood vessel with a polynucleotide, gene or genes that affect the interaction between a cell and/or its progeny and other cells in the recipient individual.
- the therapeutic gene might render the transduced cells and/or their progeny more or less susceptible to activation by other cells, more or less resistant to a chemotherapeutic agent, or more or less resistant to an infectious agent such as a virus or a toxic agent such as a chemotherapeutic drug, to name just a few examples.
- the present invention thus can be used to "deliver" any of a wide variety of genes to cells within the vasculature of a mammal, preferably a human.
- a few examples of specific therapeutic strategies taking advantage ofthe invention and its ability to transduce cells in blood vessels, especially microvessels, for recombinant gene delivery are outlined below. These additional examples are provided for purposes of further illustrating exemplary applications ofthe present invention. Numerous other genes can be delivered using the methods ofthe present invention, as will be clear to those of skill in the art.
- a number of genes can be expressed in the vasculature, especially microvessels, to increase cell growth of microvascular cells (e.g., promote angiogenesis) and/or to increase cell growth in a target tissue or organ supplied by the transduced microvessels.
- genes include, for example, human growth factors, platelet-derived growth factor (PDGF), vascular endothelial growth factors (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-beta (TGF- ⁇ ), and epidermal growth factor (EGF).
- PDGF platelet-derived growth factor
- VEGF vascular endothelial growth factors
- bFGF basic fibroblast growth factor
- TGF- ⁇ transforming growth factor-beta
- EGF epidermal growth factor
- a number of genes can be expressed in the vasculature, especially microvessels, to inhibit growth of microvascular cells and/or to decrease cell growth in a target tissue or organ supplied by transduced microvessels.
- growth factors have specific cell-surface receptors to which the respective growth factors bind to initiate their growth-promoting effects.
- the corresponding receptors have also been identified. [See, e.g., Callard, R. & Gearing, A., The Cytokine Facts Book.
- mutant receptors that, for example, bind growth factor without initiating a growth-promoting signal. This could also be achieved using soluble (e.g., secreted) forms ofthe mutant receptors. Thus, such mutant receptors could serve as antagonists for their respective growth factors; expression of such mutant receptors in cells in the vasculature, especially microvessels, which supply organs or tissues can inhibit growth of these cells and/or cells ofthe organ and tissue itself.
- inhibitors of cell growth that could be delivered to the vasculature, especially microvessels, using the methods ofthe invention include, for example, the nonphosphorylated form ofthe retinoblastoma (Rb) gene product, which inhibits cell cycle progression by binding to specific cellular transcription factors.
- Rb retinoblastoma
- large artery cell proliferation could be inhibited by over-expressing genes such as endothelial cell nitric oxide synthase (which synthesizes nitric oxide, an inhibitor of vascular smooth muscle cell proliferation) in the vasa vasorum of a parent vessel.
- the methods ofthe invention could be used to reduce atherosclerosis and restenosis following arterial reconstructions.
- numerous other genes can be expressed in the vasculature, especially microvessels, to promote cell death.
- expression of such "suicide" genes in transduced microvascular cells can result in the death of the transduced cells and death of adjacent cells in the target organ or tissue via a "bystander" effect.
- Such genes include herpes simplex virus thymidine kinase which encodes a protein rendering cells susceptibile to antiviral pro-drug ganciclovir.
- programmed cell death in cells in blood vessels, especially microvascular cells, can be promoted by over-expressing, for example, p53 tumor suppressor gene or other genes in the apoptosis pathways.
- p53 tumor suppressor gene or other genes in the apoptosis pathways.
- the rAAV vectors may also contain one or more detectable markers.
- detectable markers include, by way of illustration, the bacterial beta-galactosidase (lacZ) gene; the human placental alkaline phosphatase (“AP”) gene and genes encoding various cellular surface markers which have been used as reporter molecules both in vitro and in vivo.
- the rAAV vectors may also contain one or more selectable markers.
- the rAAV vector may also comprise a "suicide" gene that allows recipient cells in a blood vessel to be selectively eliminated at will.
- a suicide gene is a type of negative selectable marker gene that causes host cells to be inhibited or eliminated in the presence ofthe corresponding selective agent. Such suicide genes can thereby be used to selectively eliminate the host cells should that become necessary or desirable.
- Recombinant AAV vectors can also comprise polynucleotides that do not encode proteins, including, e.g., polynucleotides encoding for antisense mRNA (the complement of mRNA) which can be used to block the translation of normal mRNA by forming a duplex with it, and polynucleotides that encode ribozymes (RNA catalysts).
- polynucleotides that do not encode proteins including, e.g., polynucleotides encoding for antisense mRNA (the complement of mRNA) which can be used to block the translation of normal mRNA by forming a duplex with it, and polynucleotides that encode ribozymes (RNA catalysts).
- rAAV vectors by the methods ofthe present invention may involve use of any number of delivery techniques (both surgical and non- surgical) which are available and well known in the art.
- delivery techniques include vascular catheterization, cannulization, injection, inhalation, inunction, topical, oral, percutaneous, intra-arterial, intravenous, and/or intraperitoneal administrations.
- Vectors can also be introduced by way of bioprostheses, including, by way of illustration, vascular grafts (PTFE and dacron), heart valves, intravascular stents, intravascular paving as well as other non-vascular prostheses.
- PTFE and dacron vascular grafts
- Heart valves intravascular stents
- intravascular paving intravascular paving as well as other non-vascular prostheses.
- the methods of the present invention can be quite beneficial in a number of disease conditions in which blood vessels and/or angiogenesis play a role.
- the ability to transduce cells in blood vessels, especially microvessels, of a specific tissue or organ would allow one to locally modify gene expression and to locally enhance the tissue or organ in a positive way.
- angiogenesis There are many clinical situations associated with angiogenesis where the ability to limit or eliminate angiogenic potential using the methods ofthe present invention can be very beneficial.
- bom benign and malignant neoplasms typically require extensive blood supply to support growth and metastasis, so that inhibition of angiogenesis can be used to inhibit or eliminate these neoplasms.
- the malignant potential of many tumors can be directly correlated to the extent of microvascular content.
- the methods ofthe invention can be used to target the blood supply ofthe tumor itself and, in a minimally invasive fashion, promote its elimination without systemic or permanent side effects.
- cardiac ischemia is characterized by insufficient blood and oxygen flow to the heart and is an example of a system that would be benefited by application of the present invention.
- rAAV vectors e.g., comprising polynucleotides that can transduce and modify growth of microvascular cells in thai area
- the ability to transduce cells in blood vessels, especially microvessels, of an organ or tissue allows for gene expression that can be used to directly influence the tissue or organ supplied without necessarily affecting the microvessel itself.
- tissue such as coronary arteries blocked with atherosclerosis
- scarring frequently results in a recurrent blockage (e.g., restenosis) at the site of reconstruction.
- a recurrent blockage e.g., restenosis
- 30-60% of treated arteries develop restenosis.
- the methods ofthe invention to transduce cells in the vasa vasorum of an affected artery with, for example, an inhibitor of vascular smooth muscle cell proliferation the atherosclerosis, scarring and subsequent restenosis following such arterial reconstructions can be reduced.
- Example 1 Generation of rAAV Preparations For purposes of illustrating the present invention, the inventors prepared several rAAV vectors. For a number ofthe primary explant culture and in vivo studies described below, the inventors employed an adeno-associated virus-based vector called "ACAPSN" which comprises AAV ITR sequences, the human cytomegalovirus (CMV) promoter operably linked to the human placental alkaline phosphatase (AP) cDNA, the simian virus 40 promoter operably linked to the E. coli transposon Tn5 neomycin phosphotransferase (neo) gene, and a synthetic polyadenylation site.
- ACAPSN adeno-associated virus-based vector
- ACAPSN adeno-associated virus-based vector
- CMV human cytomegalovirus
- AP placental alkaline phosphatase
- simian virus 40 promoter operably linked to the E. coli transposon Tn5
- ACAPSN vector was as follows: the ITR sequences and plasmid backbone were derived from AAV-CFTR (which contains AAV2 nucleotides 1-145 comprising the left-hand ITR, the cystic fibrosis transmembrane regulator (CFTR) cDNA nucleotides 133 to 4573, a synthetic polyadenylation signal based on murine ⁇ -globin [See, e.g., Flotte (1), 1993] and AAV2 nucleotides 4490 to 4680 containing the right-hand ITR inserted in a plasmid backbone of pBR322 nucleotides 2295 (Ndel) to 4284 (Aat2)).
- AAV-CFTR which contains AAV2 nucleotides 1-145 comprising the left-hand ITR, the cystic fibrosis transmembrane regulator (CFTR) cDNA nucleotides 133 to 4573, a synthetic polyadenylation signal based on murine ⁇ -globin [
- the AAV-CFTR vector was digested with Xho 1 and SnaB 1 and the ITRs and plasmid backbone were gel isolated.
- An Xhol to SnaBl fragment containing a portion of the CMV promoter (nucleotides -671 to -464) [See, e.g., Boshart, 1985] was gel isolated and ligated to the ITR plasmid backbone fragment derived from AAV-CFTR to generate "pAAV- CMV (SnaBl)."
- an Spel to SnaBl fragment containing the synthetic polyadenylation signal was inserted into Spel/SnaBl digested pAAV-CMV (SnaBl) to generate "pAAV-CMV (Spel)-spA.”
- the pAAV-CMV (Spel)-spA vector contains nucleotides -671 to -584 of the CMV promoter.
- AAV-CMV-AP vector Construction of AAV-CMV-AP vector The inventors also employed a second adeno-associated virus-based vector
- AAV-CMV-AP in their primary explant culture studies.
- the construction of vector AAV-CMV-AP was as follows: the AAV vector pTRF46 [See, e.g., Flotte (1), 1993] was restriction endonuclease digested with Hind3 and Asp718 and the fragment containing the ITR sequences, synthetic polyadenylation site (and including the pBR322 derived plasmid backbone) was gel isolated.
- neomycin phosphotransferase gene which had been engineered with a Kozak consensus eukaryotic translation initiation sequence was PCR amplified using primers that gave a Hind3 site at the 5 ' end and an Asp718 site at the 3 ' end ofthe neo sequences.
- the Hind3/Asp718 digested neo PCR product was ligated to the pTRF46 derived fragment to generate "pAAVneoBR.”
- the AAV and neo sequences were excised from the pBR322 derived plasmid backbone at the Bgl2 sites flanking the ITRs and subcloned into a Bluescript vector in which the multiple cloning site was substituted with a Bgl2 linker to create "pAAVneo.”
- a Sail fragment containing the human placental alkaline phosphatase cDNA sequence was isolated from the retroviral vector DAP.
- a 2 base pair fill-in was performed and the fragment inserted into pAAVneo which had been linearized with BamHl and partially filled-in to accept the insert.
- the resulting intermediate construct "pAAVneoAP” was digested with Hind3 to remove the neo sequences.
- the construct was religated to create "pAAVAP.”
- a 2 base pair fill-in was performed on an Spel to Nhel fragment containing the CMV immediate early promoter sequences [See, e.g., Boshart, 1985] (from nucleotide -583 to +71) and then was inserted into pAAVAP which had been linearized with Hind3 and also partially filled-in.
- the resulting construct was vector "AAV-CMV-AP.”
- rAAV vectors In order to investigate the delivery of rAAV vectors to a variety of cell types typically found in blood vessels, the inventors examined the transduction of smooth muscle cells in human primary explant cultures using the AAV-CMV-AP vector.
- Human smooth muscle cells were derived from a biopsy sample by enzymatic digestion using procedures as described in the art. Primary explant cultures were characterized and confirmed to contain predominantly smooth muscle cells using immunocytochemical staining for alpha-actin, as described in Example 6 below. Cells were seeded at a density of 1x10 cells/ 12 wells such that the cultures were semi-confluent (50% coverage ofthe dish) 24 hours later at the time of exposure to AAV-CMV-AP vector.
- AAV-CMV-AP vector Cells were exposed to lO ⁇ l of AAV-CMV-AP vector in a total volume of 1 ml complete medium (containing a final concentration of 10% fetal bovine serum) for 24 hours. Smooth muscle cells were transduced with three independent preparations of AAV-CMV-AP vector. The vector preparations were estimated by slot-blot analysis of DNA genomes to contain on the order of 10 particles per ml. Transductions were thus performed with approximately 100 particles per cell. Virus was removed from the cells at the end of the 24 hour exposure period and the cells were cultured in fresh medium for an additional 24 hours.
- the cells were harvested using trypsin and 2.5 x 10 cells were transferred onto glass slides using a cytospin. The slides were allowed to air dry, and the cells were then fixed in 0.5% glutaraldehyde in PBS. The cells were washed in three changes of PBS and heat treated for 30 minutes at 65 °C to inactivate any endogenous alkaline phosphatase activity.
- the cells were incubated in 5-bromo-4- chloro-3-indolyl phosphate (X-phos, 0.1 mg/ml, Boehringer Mannheim) and nitro- blue tetrazolium (NBT, 1 mg/ml, Boehringer Mannheim, in Buffer 3 [100 mM Tris, 100 mM NaCl, 50 mM MgCl2 - pH 9.5]) for 3 hours at room temperature in the dark, which resulted in dark purple/black staining of cells expressing alkaline phosphatase.
- the slides were then rinsed in PBS and coverslipped using aqueous mounting medium.
- the percent of cells expressing alkaline phosphatase was determined by counting cells under light microscopy in at least two fields using a eye piece grid. The mean transduction frequency from the three independent infections was approximately 5.37%.
- AAV-CMV-AP Vector In order to further investigate the delivery of rAAV vectors to a variety of species, the inventors also examined the transduction of smooth muscle cells in rat primary explant cultures using the AAV-CMV-AP vector.
- Rat smooth muscle cell cultures were derived from Fischer 344 rat aorta by enzymatic digestion and confirmed to contain predominantly smooth muscle cells using immunocytochemical staining for alpha-actin, as described above. [See, e.g. ,
- Rabbit smooth muscle cells were derived from rabbit aorta by enzymatic digestion, characterized and confirmed to contain predominantly smooth muscle cells using immunocytochemical staining for alpha-actin, as described above. Cells were transduced with a single preparation of AAV-CMV-AP vector at 100 particles per cell, as described in Example 2 (a). Human and rat smooth muscle cells were also transduced for comparison purposes. Rabbit smooth muscle cells were transduced at a frequency of approximately 10.26%, or twice the frequency of human smooth muscle cell (approximately 5.41%) in the same study. Rat smooth muscle cells were again transduced at a frequency two orders of magnitude lower (approximately 0.016%).
- the inventors also examined the transduction of smooth muscle cells in monkey primary explant cultures using the ACAPSN vector.
- Smooth muscle cells were derived from a Macaca fascicularis biopsy sample by enzymatic digestion, characterized and confirmed to contain predominantly smooth muscle cells by immunocytochemical staining for alpha-actin, as described above.
- Cells were transduced with ACAPSN vector as described for human smooth muscle cell transductions in Example 2 (a), except that approximately 1000 particles per cell were used. The mean frequency of the transduction was approximately 13.19%.
- Example 2 Transduction of Umbilical Vein Endothelial Cells in Human Primary Explant Cultures Using the ACAPSN Vector.
- Human umbilical vein endothelial cells were derived from a biopsy sample following standard protocols for preparation of primary umbilical vein endothelial cell explant cultures. [See, e.g., Jaffe, 1973] Primary explant cultures were characterized and confirmed to contain predominantly endothelial cells by immunocytochemical staining for von Willebrand's Factor (vWF), as described in Example 6 below. Cells were transduced with the ACAPSN vector as described for human smooth muscle cell transductions in Example 2 (a), except that approximately 1000 particles per cell were used. The mean frequency ofthe transduction was approximately 4.56% .
- vWF von Willebrand's Factor
- Human microvascular endothelial cells were derived from omentum (fatty tissue) using enzymatic digestion and sequential plating on fibronectin coated plastic cultureware to remove contaminating fibroblasts as described in the art. Primary explant cultures were characterized and confirmed to contain predominantly endothelial cells by immunocytochemical staining for vWF, as described above.
- Example 2 fgl Transduction of Microvascular Endothelial Cells in Macaque Primary Explan Cultures Using the ACAPSN Vector
- the inventors also examined the transduction of microvascular endothelial cells in monkey primary explant cultures using the ACAPSN vector. Macaque microvascular endothelial cells were derived from omentum and characterized and confirmed to contain predominantly endothelial cells using immunocytochemical staining for vWF as described above. Cells were transduced with the ACAPSN vector as described for human smooth muscle cell transductions in Example 2 (a), except that approximately 1000 particles per cell were used. The mean frequency of the transduction was approximately 4.93%.
- the inventors conducted a series of investigations to explore the delivery of rAAV vectors to cells typically found in blood vessels (e.g., smooth muscle cells, large vessel endothelial cells, microvascular endothelial cells) from a variety of different species. It is important to emphasize that while these preliminary studies were conducted "in vitro," the inventors utilized primary explant cultures, which should be distinguished from immortalized cell cultures. Primary explant cultures, which have a finite lifespan, are believed to be far more representative of cells in vivo than immortalized cell culture lines which have generally been transformed with an oncogene so that they may grow indefinitely.
- blood vessels e.g., smooth muscle cells, large vessel endothelial cells, microvascular endothelial cells
- rAAV vectors can transfer and express a heterologous gene in a variety of the cell types typically found in blood vessels from a number of different species, including non-human primates and humans.
- Example 3 In Vivo Transduction of Microvascular Cells in Primates Using ACAPSN Introduced by Intraluminal Delivery Without Pre-Treatment The methods ofthe present invention are illustrated herein by in vivo studies conducted with non-human primates. In the following examples, the ACAPSN vector was infused into a segment of a peripheral artery in cynomolgus monkeys with established atherosclerosis.
- transductions using the methods ofthe present invention were evaluated under a variety of conditions by varying the state of the artery being treated and/or the delivery method employed.
- ACAPSN was delivered by intraluminal infusion to unperturbed femoral arteries.
- the animals received 5-bromo- 2'-deoxyuridine-5'-monophosphate (BrdU, 30 mg/kg, i.m., in saline [30 mg/ml], Boehringer Mannheim Inc., Indianapolis, IN) one and sixteen hours before surgery, to label proliferating cells for further studies (described in Example 8 below).
- the monkeys were sedated with ketamine hydrochloride (10-15 mg/kg i.m.), intubated and anesthetized with halothane gas (4% to effect). Blood was drawn for baseline serum, hematology and chemistries.
- the transduction was conducted using an ACAPSN preparation with a concentration of 3 x 10° DNAse-resistant vector particles per ml (DNAse- esistance beinu characteristic of encapsidated vector particles).
- a control 250-500 ⁇ l of Lactate Ringer's solution, "LRS" was infused into the right artery. After thirty minutes, ACAPSN vector preparation and LRS control were aspirated from the left and right arteries, respectively. The side branches were then ligated, and blood flow was re- established.
- the formalin-fixed arterial segments were stained for human placental alkaline phosphatase to localize transduced cells expressing the ACAPSN vector as follows: tissues were washed in three changes of phosphate buffered saline (PBS, 10 ml, 1 hr/wash) and heated in PBS for thirty minutes in a 65°C water bath to inactivate any endogenous alkaline phosphatase activity.
- PBS phosphate buffered saline
- Positive controls were included with each AP assay and were either: (1) cytospins of cultured smooth muscle cells transduced with the ACAPSN vector and fixed with 10% formalin; or (2) cultured smooth muscle cells transduced with the ACAPSN vector, pelleted, fixed with 10% formalin, embedded in paraffin and sectioned.
- Negative controls were included for each animal and were either: (1) sections cut from arteries infused with Lactate Ringer's Solution; or (2) sections cut from arteries remote from the site of ACAPSN treatment.
- Example 4 In Vivo Transduction of Microvascular Cells in Primates Using ACAPSN Introduced hv Intraluminal Delivery Following Denudation Pre-Treatment In order to determine whether endothelial cells function as a barrier to rAAV gene delivery deeper into the artery vessel wall, the ACAPSN vector was delivered by intraluminal infusion to carotid arteries which had been denuded of endothelium.
- ACAPSN preparation with a concentration of 3 x 10 9 DNAse-resistant particles per ml.
- the animals were generally prepped, selected and maintained as described in Example 3, with the following exceptions: (1) the carotid arteries were studied in this Example; and (2) prior to intraluminal delivery ofthe ACAPSN vector and control (to the left and right carotids, respectively), a denudation pre-treatment was given as follows.
- the carotid arteries were denuded of endothelium using a 3F
- Fogarty balloon embolectomy catheter V. Mueller Inc., McGaw Park, IL which was passed (3 times) 3 cm into each carotid artery, inflated, retrieved under gentle tension and then removed.
- Example 3 The subsequent handling and preparation of animals and tissue followed the procedures outlined in Example 3, with the following three exceptions: the treated arteries were removed after 60 hours of quarantine; and (2) animals were then sedated with ketamine (15 mg/kg, i.m.), heparinized (300 units/kg, i.v.), and transported to the necropsy suite where blood was drawn for hematologic and chemistry assessments. After an overdose of sodium pentobarbital (100 mg/kg, i.v.) the animals were exsanguinated while infusing Ringer's solution (approximately 750 cc) at 100 mm Hg. The right and left carotid arteries were perfusion- fixed in 10% formalin and then removed for analysis.
- ketamine 15 mg/kg, i.m.
- heparinized 300 units/kg, i.v.
- the ACAPSN vector was delivered by intraluminal infusion to carotid arteries which had been gently denuded and focally distended.
- ACAPSN vector preparation was generated according to the procedures of Example 1. The transduction was conducted using an ACAPSN preparation with a concentration of 1 x 10 10 DNAse-resistant particles per ml. The animals were generally prepped, selected and maintained as described in Example 3, with the following exceptions: (1) the carotid arteries were studied in this Example; and (2) prior to intraluminal delivery ofthe ACAPSN vector and control (to the left and right carotids, respectively), the carotid arteries were gently denuded of endothelium and subjected to focal over-distention. This pre-treatment was performed as follows: a 3F Fogarty balloon embolectomy catheter (V.
- J J adventitial cells that were not clearly identified as endothelial cells of both carotid arteries exposed to rAAV vector, but was not observed in either control artery.
- the ACAPSN vector was also delivered by injection directly into the adventitia of a carotid artery that had been stimulated several days prior to delivery.
- the artery was stimulated by repeated intraluminal passage of an inflated balloon catheter five days prior to delivery of ACAPSN, which would be expected to increase the rate of cellular proliferation ofthe vessel wall prior to delivery ofthe vector.
- the maximum proliferation of cells throughout the artery wall is induced within 4-7 days of balloon injury.
- An ACAPSN vector preparation was generated according to the procedures of Example 1. The transduction was conducted using an ACAPSN preparation with a concentration of 3 x 10 9 DNAse- resistant particles per ml. The animal was generally prepped, selected, and maintained as described in Example 3, with the following four exceptions: ( 1 ) the carotid arteries were studied in this Example; (2) both carotids received the
- ACAPSN vector preparation was injected per side, directly into the subadventitial plane, using a 1 cc syringe and 27 gauge needle.
- Example 4 The subsequent handling and preparation of animals and tissue followed the procedures outlined in Example 4, with the following exceptions: ( 1 ) the treated arteries were removed after 72 hours of quarantine; and (2) immunocytochemical analysis was performed on tissue taken from the right carotid as follows.
- endothelial cell vWF, DAKO
- macrophage CD-68, DAKO
- lymphocyte CD-3, DAKO
- Primary antibodies were localized with appropriate biotinylated secondary antibodies (Vector Laboratories Inc.) and tertiary avidin-biotin-peroxidase staining (Vector Laboratories Inc.). Sections were counter- stained with hematoxylin and examined by standard light-microscopy. For the right carotid, much ofthe AP activity co-localized with cells staining for either endothelial cell or smooth muscle cell markers. A minority of the AP activity co-localized with cells staining for a macrophage marker.
- a number of AP positive cells could not be positively identified with these cell type-specific antibodies.
- a very high frequency of expression was observed in cells identified histologically within adventitial microvessels For this artery, expression was also observed in a significant number of other cells in the adventitia at the region of injection; as described above, these were not positively identified with cell-type specific antibodies and could possibly be, for example, fibroblasts, lymphocytes, other leukocytes, and nerve cells
- a small number of AP positive cells was observed, and these few cells were predominantly associated with structures histologically consistent with microvessels
- adventitial microvessels are believed to be supplied with blood from the lumen of the parent vessel (e.g., the artery) via small microvessels traversing the vessel media.
- This study was designed to demonstrate that introduction of an rAAV vector into the adventitia can also be achieved indirectly, by injection directly into the lumen of an artery that had been pre-treated by prior balloon injury.
- the artery was stimulated by repeated intraluminal passage of a large inflated balloon catheter five days prior to delivery of ACAPSN, which would be expected to increase the rate of cellular proliferation of the vessel wall prior to delivery of the vector.
- An ACAPSN vector preparation was generated according to the procedures of Example 1. The transduction was conducted using an ACAPSN preparation with a concentration of 1 x 10 10 DNAse-resistant particles per ml. The animal was generally prepped, selected and maintained as described in Example 6, with the following exception: delivery occurred by intraluminal delivery as described in Example 3. Thus, in this Example, (1) both carotids received
- the right carotid artery was subjected to balloon injury by three intraluminal passages of an inflated 3F Fogarty balloon catheter (V. Mueller Inc., McGaw Park, IL) under moderate tension.
- the left carotid was previously unmanipulated..
- the subsequent handling and preparation of animals and tissue followed the procedures outlined in Example 4, with the exception that the treated arteries were removed after 72 hours of quarantine.
- the ability to successfully transduce cells in blood vessels in an atherosclerotic macaque model using the methods ofthe present invention indicates that transduction of atherosclerotic vessels can be achieved and that even higher levels of transduction may be achieved in non-atherosclerotic vessels in which access conditions are less stringent.
- the BrdU data may provide further confirmation that rAAV uptake and expression is associated with cells that are proliferating, such as those associated with angiogenesis.
- angiogenesis models such as ocular microvascular cells or egg-yolk sac models can be used to quantify similar results in primary tissue in primary cells.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61066096A | 1996-03-04 | 1996-03-04 | |
PCT/US1997/003134 WO1997032990A1 (en) | 1996-03-04 | 1997-02-28 | Methods for transducing cells in blood vessels using recombinant aav vectors |
US610660 | 2003-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0906440A1 true EP0906440A1 (de) | 1999-04-07 |
Family
ID=24445931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97907934A Withdrawn EP0906440A1 (de) | 1996-03-04 | 1997-02-28 | Verfahren zur transduktion von zellen in blutgefässen unter verwendung von rekombinanten aav vektoren |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0906440A1 (de) |
JP (1) | JP2002514899A (de) |
AU (1) | AU1980697A (de) |
CA (1) | CA2247099A1 (de) |
WO (1) | WO1997032990A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US5652224A (en) | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
US5941868A (en) * | 1995-12-22 | 1999-08-24 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
EP0888086B1 (de) | 1996-02-15 | 2005-07-27 | Biosense Webster, Inc. | Sonde zur exkavation |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
JP2001520051A (ja) * | 1997-10-21 | 2001-10-30 | ターゲテッド ジェネティックス コーポレイション | 組換えaavベクターの産生のための増幅可能アデノ随伴ウイルス(aav)パッケージングカセット |
ES2293473T3 (es) | 1998-02-05 | 2008-03-16 | Biosense Webster, Inc. | Administracion intracardiaca de farmaco. |
US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US6537540B1 (en) | 1999-05-28 | 2003-03-25 | Targeted Genetics Corporation | Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
WO2001009360A1 (en) * | 1999-08-02 | 2001-02-08 | Avigen, Inc. | USE OF RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR (rAAV) FOR THE PREVENTION OF SMOOTH MUSCLE CELL PROLIFERATION IN A VASCULAR GRAFT |
ES2308989T3 (es) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
EP1916258B1 (de) | 1999-08-09 | 2014-04-23 | Targeted Genetics Corporation | Erweiterte Expression einer einstämmigen, heterologen Nukleotidsequenz von rekombinanten viralen Vektoren durch Modellierung der Sequenz mit stammübergreifenden Basispaaren |
EP1870473A1 (de) * | 2000-08-17 | 2007-12-26 | Keiya Ozawa | Durch adenoassoziierte Viren vermittelte Freigabe von Angiogenesefaktoren |
ES2288993T3 (es) * | 2000-08-17 | 2008-02-01 | Keiya Ozawa | Distribucion de factores angiogenicos mediada por virus adenoasociados. |
JP5879256B2 (ja) | 2009-05-02 | 2016-03-08 | ジェンザイム・コーポレーション | 神経変性障害のための遺伝子治療 |
WO2012145509A2 (en) | 2011-04-19 | 2012-10-26 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors, and viruses |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658565A (en) * | 1994-06-24 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inducible nitric oxide synthase gene for treatment of disease |
DK0733103T3 (da) * | 1993-11-09 | 2004-07-12 | Univ Johns Hopkins | Fremstilling af höje titre af rekombinante AAV vektorer |
EP0750503A4 (de) * | 1994-03-07 | 1999-07-21 | Immusol Inc | Ribozymtherapie für restenose |
US6162796A (en) * | 1995-09-27 | 2000-12-19 | The Rockefeller University | Method for transferring genes to the heart using AAV vectors |
-
1997
- 1997-02-28 CA CA 2247099 patent/CA2247099A1/en not_active Abandoned
- 1997-02-28 EP EP97907934A patent/EP0906440A1/de not_active Withdrawn
- 1997-02-28 JP JP53184097A patent/JP2002514899A/ja active Pending
- 1997-02-28 AU AU19806/97A patent/AU1980697A/en not_active Abandoned
- 1997-02-28 WO PCT/US1997/003134 patent/WO1997032990A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9732990A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002514899A (ja) | 2002-05-21 |
WO1997032990A1 (en) | 1997-09-12 |
CA2247099A1 (en) | 1997-09-12 |
AU1980697A (en) | 1997-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997032990A1 (en) | Methods for transducing cells in blood vessels using recombinant aav vectors | |
US5693531A (en) | Vector systems for the generation of adeno-associated virus particles | |
US7078387B1 (en) | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors | |
Ponnazhagan et al. | Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo | |
US5780447A (en) | Recombinant adeno-associated viral vectors | |
US20060292117A1 (en) | Improved rAAv vectors | |
EP0844887B1 (de) | Die transduktion von myoblasten mittels vektoren aus adenoassoziierten viren | |
Raper et al. | Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses | |
US20020001581A1 (en) | Methods for transducing cells in blood vessels using recombinant AAV vectors | |
Eslami et al. | Gene delivery to in situ veins: differential effects of adenovirus and adeno-associated viral vectors | |
CA2274146C (en) | Genetic modification of primate hemopoietic repopulating stem cells | |
Conte et al. | Genetic interventions for vein bypass graft disease: a review | |
US20020159978A1 (en) | Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions | |
CN102712920A (zh) | 缺氧调节的条件沉默性aav表达血管生成诱导因子 | |
AU763049B2 (en) | Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors | |
US20100028312A1 (en) | Stably transformed bone marrow-derived cells and uses thereof | |
AU2646901A (en) | Methods for transducing cells in blood vessels using recombinant AAV vectors | |
Peeters et al. | Expansion of donor hepatocytes after recombinant adenovirus-induced liver regeneration in mice | |
WO1999064569A1 (en) | Methods and compositions for generating recombinant adeno-associated virus vectors | |
WO2000056368A1 (fr) | Therapeutique genique | |
CN110760542A (zh) | 一种共表达znf580和vegf165双基因的质粒及应用 | |
Raper et al. | Ex vivo hepatocyte-directed gene therapy | |
WO2003024384A2 (en) | Improved methods for treatment with viral vectors | |
Lin et al. | Disease-Inducible Transgene Expression | |
Miyake et al. | 900. Development of models for RPS19 deficient diamond-blackfan anemia using regulatable expression of siRNA against RPS19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980831 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20030902 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040113 |